Trials / Completed
CompletedNCT00316186
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
An Open-label Phase II Study of Weekly Intravenous Hycamtin and Carboplatin as First-line Treatment of Chemonaive Subjects With Extensive Disease Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people with extensive disease small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | topotecan | Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC. |
| DRUG | carboplatin | Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC. |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2009-03-01
- Completion
- 2009-05-01
- First posted
- 2006-04-20
- Last updated
- 2015-05-07
- Results posted
- 2009-09-29
Locations
13 sites across 2 countries: United States, Poland
Source: ClinicalTrials.gov record NCT00316186. Inclusion in this directory is not an endorsement.